Steve - We have some similarities with our CLL journeys. I started Ibrutinib in Oct 2018 and added Venetoclax trial in Aug 21. Finished trial in June 23 with uMRD. Just had CloneSeq on bloods last month and still well below uMRD. Ramp up for Ven is a bit of a commitment with some limited risks, but seems much less than jumping to the CAR-T. Best wishes and thoughts for you.
In my case, the Ibrutinib was still working well and tolerated, but would never get me to uMRD. The chance to get off all meds for a period of time was the key to joining the I+V trial. I think that I will probably be back to Ibrutinib (or similar) when next treatment needs to start - expect it to work again next time but wouldn't guess effectiveness or durability.
your experience of pirtobrutinib is typical - short duration remission. It’s a useful bridging therapy to be able to get to transplant or CAR-T for those that have exhausted all else and definitely preferable to Idelasilib.
We just went for an appointment at PMH with my husbands' oncologist and he told us that they are starting a new trial with a BTk degrader. I don't know any other details. My husband is taking zanubrutinib right now.
Hi Ileana, I just read this article online which was quite encouraging regarding BTK Degraders.
Further, one of the patients who had developed treatment resistance to pirtobrutinib after 2 years of treatment as well as other therapies experienced symptom and quality-of-life improvements after receiving NX-2127
Venetoclax is doing wonders for me too. It looks like patients will be able to take it at least two times. Sonrotoclax should be approved in 2025. A recent paper I read said it will be effective even if you develop resistance to Venetoclax. There are also multiple degraders and CAR-T therapies in trials. We all have some good options.
my CBC stayed in normal range for about a year after I had started relapsing on Ibrutinib. Lymphocytes crept up, total ALC and % of lymphocytes increased even though my overall WBC didn’t move too much—my neutrophils had been decreasing slightly. What you’re describing isn’t abnormal
BTK mutation occurred before my actual relapse by CBC. I officially relapsed when the ALC showed a clear upward trend. Your relapse appears preferential to the nodes so any increase above the normal 10-12 mm should be considered progressive disease. Same with spleen increase beyond upper size limits
Sorry to hear about your journey with Pirtobrutinib. I am on the same trial as you at PMH and at first was randomized to Arm 2 which was Idelalisib + Rituximab. That only lasted approx. 6 months before severe complications from the Idelalisib ended me up in hospital for 10 days. The weird thing was the drug was actually controlling my CLL. At that time before I was transferred over to Pirtobrutinib they said I have options, V & R, or a new trial with the degrader and Cart-T. We decided to stick with the Pirto and keep my options open if and when Pirto stopped working. I will be following what your decisions will be. Good luck, Jack
As the pirto usually is used as a bridge to the other treatments you listed, will you wait for relapse or if you hit a low level of disease go with one of the other options?
Hey Jack, I have an appt at PMH in July at which time there will be a discussion about which route to take. I have read some good things about the BTK degrader so we’ll see.
I am down at PMH on July 17th for my monthly checkup and if things are still going well I will be onto every 3 months🤞. So far so good but it took me about 4 months after the Idelalisib complications to finally be clear enough to go on Pirto. I have also heard good things about the degrader but I'm still not there for the Cart-t as of yet but will decide when the need arises. I am leaning toward the V & R next though.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.